Cellectis (CLLS) EBT Margin Growth (3y) (2018 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBT Margin Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 6,691.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2,054.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8,006.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,980.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -5,319.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 31,363.00 |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -296,228.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -296,228.00 |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | -1,320.00 |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 154,823.00 |
| Mar 31, 2025 | 35,967.00 |
| Dec 31, 2024 | -23,240.00 |
| Sep 30, 2024 | 52,776.00 |
| Jun 30, 2024 | 1,903.00 |
| Mar 31, 2024 | 29,650.00 |
| Dec 31, 2023 | -4.20 Mn |
| Sep 30, 2023 | 5,440.00 |
| Jun 30, 2023 | 379,967.00 |
| Mar 31, 2023 | -1.58 Mn |
| Dec 31, 2022 | 85,263.00 |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | 159,450.00 |
| Mar 31, 2022 | 189,409.00 |
| Dec 31, 2021 | 295,448.00 |
| Sep 30, 2021 | 268,057.00 |